|
Oxford BioDynamics PLC on Monday said its EpiSwitch blood test has demonstrated significant potential as a fast and accurate prostate cancer screening diagnostic. The Oxford-based biotechnology firm focused on discovery and development of epigenetic biomarkers said the prostagram screening pilot study of 147 men enrolled on the study, as well as patients form Imperial College NHS Trust, indicated an accuracy of 94%. The Prostate Screening EpiSwitch blood test was built using the company’s EpiSwitch 3D genomics platform. Oxford Bio said the test ‘captures a personal, systemic fingerprint of specific regulatory network changes associated with prostate cancer.’ The study - a collaboration between Oxford Bio, Imperial College London, University of East Anglia and Imperial College NHS Trust - showed a 92% positive predictive value and a 94% negative predictive value, Oxford Bio said. The company said the widely available prostate-specific antigen test is considered inaccurate, often reporting false positive results. Oxford Bio said its PSE test therefore has ‘unprecedented potential’, and can reduce unnecessary referrals to expensive and invasive procedures. Chief Executive Officer Jon Burrows said: ‘[Oxford Bio’s] EpiSwitch 3D genomics platform has once again demonstrated the ability to provide a clinically important diagnostic solution to the global medical community; this time as a highly relevant screening test for prostate cancer. ‘This is another example of how [Oxford Bio’s] product portfolio can contribute to reducing the total cost of care for global health.’ Oxford BioDynamics shares were up 10% trading at 16.81 pence per share on Monday morning in London. Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
